Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Company Deals

Insilico Medicine and Bora Pharmaceuticals Forge $2.5B Strategic Alliance to Pioneer AI-Driven Drug R&D

Fineline Cube Jul 15, 2026
Company Deals

CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem

Fineline Cube Jul 14, 2026
Policy / Regulatory

China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration

Fineline Cube Jul 14, 2026
Company Drug

Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer

Fineline Cube Jul 15, 2026
Company Drug

Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC

Fineline Cube Jul 15, 2026
Company Deals

Deep Surgery Secures Pre-Series A Funding for Microsurgery Robot Expansion

Fineline Cube Jun 10, 2025

Guangzhou-based microsurgery robot developer Deep Surgery has secured “tens of millions” of renminbi in a...

Company

ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy

Fineline Cube Jun 10, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as...

Company Drug

Hengrui Pharmaceuticals Launches Aiweida for HER2-Mutated NSCLC in China

Fineline Cube Jun 10, 2025

China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the first commercial shipment of its...

Company Medical Device

Suzhou Sinus Medtech Wins FDA Breakthrough Designation for oHCM Ablation System

Fineline Cube Jun 10, 2025

Suzhou Sinus Medical Technologies Co., Ltd., a China-based medical device innovator, announced that its in-house...

Company Drug

Novartis’ PSMAddition Trial Yields Positive Results for Pluvicto in mHSPC

Fineline Cube Jun 10, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced the interim results from its Phase III PSMAddition...

Company Drug

Innovent Biologics’ Xinbiyue Approved for Macau Market

Fineline Cube Jun 10, 2025

China-based Innovent Biologics Inc. (HKG: 1801) announced that it has received market approval from the...

Company Deals

Innogen Pharma Resubmits Hong Kong IPO Application With Promising Diabetes Drug

Fineline Cube Jun 10, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. has resubmitted its application for a main board...

Company Deals

Harrow Signs Licensing Deal for Formosa’s Byqlovi in US Market

Fineline Cube Jun 10, 2025

US-based ophthalmic pharmaceutical company Harrow (NASDAQ: HROW) announced a licensing agreement with Taiwan-based Formosa Pharmaceuticals...

Company Drug

FDA Approves Merck’s Enflonsia for Infant RSV Protection

Fineline Cube Jun 10, 2025

The US Food and Drug Administration (FDA) granted approval to Merck, Sharp & Dohme’s (MSD;...

Company Drug

Sino Biopharmaceutical Gains CDE Approval for TQC3721 COPD Trial

Fineline Cube Jun 10, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the Center...

Company Drug

Huadong Medicine’s HDM1010 Gets FDA Nod for Phase I Trial in T2D

Fineline Cube Jun 10, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...

Company Deals

Sanyou Biopharma Partners with Medicovestor to Advance Next-Gen ADCs

Fineline Cube Jun 10, 2025

China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced a strategic partnership with US-headquartered Medicovestor, Inc. to...

Company

Huahai Pharma Receives FDA Warning Letter After Inspection

Fineline Cube Jun 10, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received a warning...

Company

Burning Rock Reports Q1 2025 Revenue Growth and R&D Progress

Fineline Cube Jun 9, 2025

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) released its Q1 2025 financial report, showing a...

Company Deals

Sinopep Allsino Partners with Vazyme to Advance Synthetic Biology

Fineline Cube Jun 9, 2025

China-based Jiangsu Sinopep Allsino Biopharmaceutical Co., Ltd. (SHA: 688076) announced a strategic partnership with compatriot...

Company Deals

CIRC and Qianlong International Collaborate to Advance BNCT and Nuclear Medicine

Fineline Cube Jun 9, 2025

China Isotope & Radiation Corporation (CIRC; HKG: 1763) and Hong Kong-based Qianlong International Holdings Ltd....

Company Drug

AstraZeneca’s Calquence Combo Approved by EU for CLL Treatment

Fineline Cube Jun 9, 2025

UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) announced that the European Commission (EC) has approved its...

Company Drug

Bayer’s CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD

Fineline Cube Jun 9, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study,...

Company Deals

Lifetech Scientific Plans RMB 150 Million Investment in AffectOR MedTech

Fineline Cube Jun 9, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) announced plans to invest RMB 150 million (USD 21...

Company Deals

OBI Pharma Partners with TegMine to Develop Antibody-Drug Conjugates

Fineline Cube Jun 9, 2025

Taiwan-based OBI Pharma announced a collaboration with San Francisco-based TegMine Therapeutics, Inc. to develop antibody-drug...

Posts pagination

1 … 176 177 178 … 695

Recent updates

  • Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics
  • Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger
  • Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access
  • Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer
  • Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Company Drug

Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.